<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834964</url>
  </required_header>
  <id_info>
    <org_study_id>02354</org_study_id>
    <nct_id>NCT00834964</nct_id>
  </id_info>
  <brief_title>Venlafaxine 25 mg Tablets Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Venlafaxine 25 mg Tablets and Effexor® 25 mg Tablets Administered as 1 x 25 mg Tablet in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of venlafaxine 25&#xD;
      mg tablets (test) versus Effexor® (reference) administered as 1 x 25 mg tablet under fasting&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration - Venlafaxine in Plasma</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Bioequivalence based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Venlafaxine in Plasma</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Bioequivalence based on AUC0-inf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Venlafaxine in Plasma</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Bioequivalence based on AUC0-t</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - O-Desmethylvenlafaxine in Plasma</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Informational Purposes Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf - O-Desmethylvenlafaxine in Plasma</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Informational Purposes Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - O-Desmethylvenlafaxine in Plasma</measure>
    <time_frame>Blood samples collected over24 hour period</time_frame>
    <description>Informational Purposes Only</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effexor®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine 25 mg Tablets</intervention_name>
    <description>1 x 25 mg, single-dose fasting</description>
    <arm_group_label>Venlafaxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effexor® 25 mg Tablets</intervention_name>
    <description>1 x 25 mg, single-dose fasting</description>
    <arm_group_label>Effexor®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be females and/or males, non-smokers, 18 years of age and older. Female&#xD;
             subjects will be post-menopausal or surgically sterilized.&#xD;
&#xD;
          -  Post-menopausal status is defined as absence of menses for the past 12 months or&#xD;
             hysterectomy with bilateral oophorectomy at least 6 months ago.&#xD;
&#xD;
          -  Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal ligation at&#xD;
             least 6 months ago.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks of the administration of study&#xD;
             medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks of the administration of study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical sub-investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive urine drug screen at screening.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or&#xD;
             over 90 mmHg; or heart rate less than 50 or over 100 bpm) at screening.&#xD;
&#xD;
          -  Subjects with BMI ≥ 30.0.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than fourteen units of alcohol per week (1 Unit&#xD;
             - 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)&#xD;
             within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine&#xD;
             (PCP) and crack) within 1 year of the screening visit.&#xD;
&#xD;
          -  History of allergic reactions to venlafaxine.&#xD;
&#xD;
          -  History of allergic reactions to heparin.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;&#xD;
             examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin,&#xD;
             ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior&#xD;
             to administration of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  History or presence of any clinically significant gastrointestinal pathology (e.g.&#xD;
             chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms&#xD;
             (e.g. diarrhea, vomiting), liver or kidney disease or other conditions known to&#xD;
             interfere with the absorption, distribution, metabolism or excretion of the drug.&#xD;
&#xD;
          -  Any history or presence of clinically significant neurological, endocrinal,&#xD;
             cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products (including natural food supplements, vitamins,&#xD;
             garlic as a supplement) within 7 days prior to administration of study medication,&#xD;
             except for topical products without systemic absorption.&#xD;
&#xD;
          -  Positive alcohol breath test at screening.&#xD;
&#xD;
          -  Subjects who have used tobacco in any form within the 90 days preceding study drug&#xD;
             administration.&#xD;
&#xD;
          -  Intolerance to venipuncture.&#xD;
&#xD;
          -  Subjects with a clinically significant history of tuberculosis, epilepsy, asthma,&#xD;
             diabetes, psychosis, or glaucoma will not be eligible for this study.&#xD;
&#xD;
          -  Subjects who are unable to understand or unwilling to sign the Informed Consent Form.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             medical sub-investigator, contraindicates the subject's participation in this study.&#xD;
&#xD;
          -  Subjects who have had a depot injection or an implant of any drug 3 months prior to&#xD;
             administration of study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 Days. Donation or loss of whole blood prior to&#xD;
             administration of the study medication as follows: less than 300 mL of whole blood&#xD;
             within 30 days or; 300 mL to 500 mL of whole blood within 45 days or; more than 500 mL&#xD;
             of whole blood within 56 days.&#xD;
&#xD;
          -  Subjects who have consumed food or beverages containing grapefruit (e.g. fresh,&#xD;
             canned, or frozen) within 7 days prior to administration of the study medication.&#xD;
&#xD;
          -  Subjects with known presence of volume-depletion.&#xD;
&#xD;
          -  Subjects predisposed to bleeding of the skin and mucous membrane.&#xD;
&#xD;
          -  Subjects with history or known presence of impaired platelet aggregation.&#xD;
&#xD;
          -  Subjects with history of seizures.&#xD;
&#xD;
          -  Breast-feeding subjects.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening (performed on all females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>GIV2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>July 6, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>September 11, 2009</last_update_submitted>
  <last_update_submitted_qc>September 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Venlafaxine (Test) First</title>
          <description>Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Effexor® (Reference) First</title>
          <description>Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout: 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Venlafaxine (Test) First</title>
          <description>Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Effexor® (Reference) First</title>
          <description>Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration - Venlafaxine in Plasma</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>Venlafaxine 25 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Effexor®</title>
            <description>Effexor® 25 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration - Venlafaxine in Plasma</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.11" spread="19.19"/>
                    <measurement group_id="O2" value="39.91" spread="20.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>97.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.72</ci_lower_limit>
            <ci_upper_limit>101.49</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Venlafaxine in Plasma</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>Venlafaxine 25 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Effexor®</title>
            <description>Effexor® 25 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Venlafaxine in Plasma</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327.78" spread="447.01"/>
                    <measurement group_id="O2" value="309.75" spread="367.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>99.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>94.74</ci_lower_limit>
            <ci_upper_limit>104.92</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Venlafaxine in Plasma</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>Venlafaxine 25 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Effexor®</title>
            <description>Effexor® 25 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Venlafaxine in Plasma</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.66" spread="266.95"/>
                    <measurement group_id="O2" value="273.03" spread="260.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>98.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>93.46</ci_lower_limit>
            <ci_upper_limit>104.02</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - O-Desmethylvenlafaxine in Plasma</title>
        <description>Informational Purposes Only</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>Venlafaxine 25 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Effexor®</title>
            <description>Effexor® 25 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - O-Desmethylvenlafaxine in Plasma</title>
          <description>Informational Purposes Only</description>
          <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.01" spread="22.83"/>
                    <measurement group_id="O2" value="62.07" spread="22.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>96.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>91.96</ci_lower_limit>
            <ci_upper_limit>100.82</ci_upper_limit>
            <estimate_desc>Metabolite results not subjected to bioequivalence criteria; results are presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf - O-Desmethylvenlafaxine in Plasma</title>
        <description>Informational Purposes Only</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>Venlafaxine 25 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Effexor®</title>
            <description>Effexor® 25 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - O-Desmethylvenlafaxine in Plasma</title>
          <description>Informational Purposes Only</description>
          <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1181.30" spread="478.25"/>
                    <measurement group_id="O2" value="1123.62" spread="415.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>104.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100.08</ci_lower_limit>
            <ci_upper_limit>108.29</ci_upper_limit>
            <estimate_desc>Metaboite results not subjected to bioequivalence criteria, results are presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - O-Desmethylvenlafaxine in Plasma</title>
        <description>Informational Purposes Only</description>
        <time_frame>Blood samples collected over24 hour period</time_frame>
        <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>Venlafaxine 25 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Effexor®</title>
            <description>Effexor® 25 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - O-Desmethylvenlafaxine in Plasma</title>
          <description>Informational Purposes Only</description>
          <population>Data from first 24 completed subjects were included in the statistical analysis per protocol.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="844.35" spread="316.73"/>
                    <measurement group_id="O2" value="838.37" spread="306.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>100.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>97.30</ci_lower_limit>
            <ci_upper_limit>103.84</ci_upper_limit>
            <estimate_desc>Metabolite results were not subjected to bioequivalence criteria, results are presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

